SEOM clinical guidelines for the treatment of follicular non-Hodgkin’s lymphoma

被引:0
作者
Delvys Rodríguez-Abreu
Marta Llanos Muñoz
Mariano Provencio Pulla
Antonio Rueda Domínguez
Dolores Isla Casado
机构
[1] Hospital Universitario Insular de Gran Canaria,Servicio de Oncología Médica
[2] Hospital Universitario de Canarias,Servicio de Oncología Médica
[3] Hospital Universitario Puerta de Hierro,Servicio de Oncología Médica
[4] Hospital Costa del Sol de Marbella,Servicio de Oncología Médica
[5] Hospital Clínico Universitario Lozano Blesa,Servicio de Oncología Médica
来源
Clinical and Translational Oncology | 2010年 / 12卷
关键词
Follicular lymphoma; Rituximab; FLIPI; Guideline; Novel treatments;
D O I
暂无
中图分类号
学科分类号
摘要
Follicular lymphoma (FL) is the second most common subtype of non-Hodgkin’s lymphoma (NHL) in the Western world. FL constitutes the most frequent indolent lymphoma, well characterized by its clinical presentation related to nodal involvement and its morphologic and biologic features. It is often managed as an incurable disease. However, several active therapeutic approaches from the ‘wait and watch” strategy to the allogeneic transplantation are available for management of patients with FL and clearly have changed the natural history of this disease, achieving a long-term disease-free survival. Therapeutic decision is mostly conditioned by patient’s characteristics, stage, histological grade, tumor burden, and risk-predicting factors. This article try to summarizes the diagnosis and treatment of this heterogeneous group of patients.
引用
收藏
页码:760 / 764
页数:4
相关论文
共 48 条
[1]  
Tan D.(2008)Follicular lymphoma: clinical features and treatment Hematol Oncol Clin North Am 22 863-882
[2]  
Horning S.(1989)Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin’s Lymphoma: Costwolds meeting J Clin Oncol 7 1630-1636
[3]  
Lister T.A.(2004)The Follicular Lymphoma Prognostic Index (FLIPI) Blood 104 1258-1265
[4]  
Crowder D.(2006)Long-term outcome and mortality trends in earlystage, grade 1–2 follicular lymphoma treated with radiation therapy Int J Radiat Oncol Biol Phys 64 928-934
[5]  
Sutcliffe S.B.(2003)Longterm follow-up of a prospective study of combined modality therapy for stage I–II indolent non-Hodgkin’s lymphoma J Clin Oncol 21 2115-2122
[6]  
Solal-Celigny P.(2004)Stage I and II follicular non-Hodgkin’s lymphoma: long-term follow-up of no initial therapy J Clin Oncol 22 1454-1459
[7]  
Roy P.(1988)The treatment of indolent lymphomas: watchful waiting v aggressive combined modality treatment Semin Hematol 25 11-16
[8]  
Dreyling M.(2006)Combined immunochemotherapy with rituximab improves overall survival in patients with follicular and mantle cell lymphoma: updated meta-analysis results [Abstract] Blood 108 A-2760
[9]  
Guadagnolo B.A.(2008)Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin’s lymphoma J Clin Oncol 26 4473-4479
[10]  
Li S.(2004)Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly × 4 schedule Blood 103 4416-4423